IBRX

Immunitybio Inc

IBRX.US immunitybio.com + Research + Basket
CIK 0001326110
Employees 684
Phone 844 696 5235
Fiscal year end December
IPO Jul 28, 2015
Address 3530 John Hopkins Court, San Diego, CA, United States, 92121
8.01
-0.92 (-10.30%)
USD · NASDAQ
52-week range
1.95
12.43
Trading at 58% of the 52-week range
Market Cap
9.46B
P/E Ratio
0.00
Forward P/E
83.33
Book Value
-0.99
Div. Yield
N/A
% Institutions
19.94%
% Insiders
62.16%

1 Year

+272.6%

3 Year

+122.5%

10 Year

+28.6%
Description

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Actions

Add an action for IBRX.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., M.S., M.Sc. Founder, Executive Chairman and Global Chief Scientific & Medical Officer 1953
Mr. Richard Gerald Adcock President, CEO & Director 1969
Mr. David C. Sachs Chief Financial Officer 1978
Ms. Regan J. Lauer Chief Accounting Officer 1970
Dr. Barry J. Simon M.D. Chief Corporate Affairs Officer & Director 1965
Dr. Enrique Diloné Ph.D., RAC Chief Technology Officer 1967
Ms. Sarah Singleton Chief Communications Officer & Head of Patient Advocacy NA
Ms. Emily Arison Senior Vice President of Human Resources NA
Dr. Leonard S. Sender M.D. Chief Medical Officer of Liquid Tumors & Cell Therapy NA
Dr. Sandeep K. Reddy M.D. Chief Medical Officer NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Feb 24, 2026 Barry J Simon N/A Sale 75.00K $12.01 $900.75K SEC
Feb 23, 2026 Barry J Simon N/A Sale 165.00K $10.25 $1.69M SEC
Feb 23, 2026 Christobel Selecky N/A Sale 25.00K $10.00 $250.00K SEC
Feb 20, 2026 Barry J Simon N/A Sale 10.00K $9.25 $92.50K SEC
Jan 20, 2026 Barry J Simon N/A Sale 151.97K $7.20 $1.09M SEC
Jan 20, 2026 Christobel Selecky N/A Sale 25.00K $7.51 $187.75K SEC
Jan 16, 2026 Christobel Selecky N/A Sale 50.00K $5.00 $250.00K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 34.08M Jun 30, 2026 3.22% $0.00 29.37%
State Street Corp 21.40M Jun 30, 2026 2.02% $0.01 20.84%
Vanguard Portfolio Management, LLC 17.86M Jun 30, 2026 1.69% $0.01 9.44%
Vanguard Capital Management, LLC 15.69M Jun 30, 2026 1.48% $0.00 3.73%
D. E. Shaw & Co LP 11.55M Jun 30, 2026 1.09% $0.05 -8.12%
Two Sigma Investments LLC 11.10M Jun 30, 2026 1.05% $0.07 153.04%
Geode Capital Management, LLC 9.85M Jun 30, 2026 0.93% $0.00 22.61%
Millennium Management LLC 5.58M Jun 30, 2026 0.53% $0.02 292.88%
Northern Trust Corp 3.57M Jun 30, 2026 0.34% $0.00 42.34%
Morgan Stanley - Brokerage Accounts 3.43M Jun 30, 2026 0.32% $0.00 -14.59%
The Goldman Sachs Group Inc 3.23M Jun 30, 2026 0.31% $0.00 -0.09%
UBS Group AG 3.20M Jun 30, 2026 0.30% $0.00 8.52%
Charles Schwab Investment Management Inc 2.89M Jun 30, 2026 0.27% $0.00 16.57%
Woodline Partners LP 2.50M Jun 30, 2026 0.24% $0.07 -27.48%
SEB Asset Management AB 2.45M Jun 30, 2026 0.23% $0.08 0.00%
Vanguard Fiduciary Trust Co 2.41M Jun 30, 2026 0.23% $0.00 13.62%
Bank of America Corp 2.18M Jun 30, 2026 0.21% $0.00 -10.76%
VOLORIDGE INVESTMENT MANAGEMENT, LLC 1.72M Jun 30, 2026 0.16% $0.06 -41.18%
Federated Hermes Inc 1.71M Jun 30, 2026 0.16% $0.02 23.55%
Royal Bank of Canada 1.54M Jun 30, 2026 0.15% $0.00 3.81%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 13.52M 1.28% ▲ 16.30% Sep 30, 2026
2 State Street® SPDR® S&P® Biotech ETF 12.23M 1.15% ▼ 0.80% Oct 29, 2026
3 iShares Russell 2000 ETF 9.80M 0.92% ▼ 0.41% Oct 29, 2026
4 Vanguard Small Cap Index 9.55M 0.90% ▲ 13.26% Sep 30, 2026
5 Vanguard MStar Small Cap Growth Indx Inv 5.24M 0.49% ▲ 8.64% Sep 30, 2026
6 Fidelity Small Cap Index 4.22M 0.40% ▲ 0.83% Jul 31, 2026
7 iShares Russell 2000 Growth ETF 3.64M 0.34% ▲ 0.25% Oct 29, 2026
8 iShares Biotechnology ETF 3.07M 0.29% ▼ 0.19% Oct 29, 2026
9 SEB Läkemedelsfond A (SEK) 2.45M 0.23% ▲ 0.00% Sep 30, 2026
10 Vanguard Russell 2000 ETF 2.25M 0.21% ▲ 1.13% Sep 30, 2026

Financial Highlights

▼
Market Cap: $9.46B
EBITDA: $-235.30M
Book Value: $-0.99
Earnings/Share: $-0.96
Profit Margin: 0.00%
Operating Margin: -120.41%
ROA (TTM): -30.54%
ROE (TTM): 0.00%
Revenue (TTM): $165.79M
Revenue/Share (TTM): $0.17
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 93.90%

Valuation Metrics

Enterprise Value: $9.26B
Trailing P/E: 0.00
Forward P/E: 83.33

Shares Statistics

Shares Outstanding: 1.06B
Shares Float: 406.69M
% Insiders: 62.16%
% Institutions: 19.94%
Shares Short: 122.95M
Shares Short (Prior Month): 124.09M
Short Ratio: 7.96
Short % Float: 30.67%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$113.29M
Cost of Goods Sold
adjust
$-753.00K
Gross Profit
subtotal
$112.54M
SG&A
adjust
$-150.00M
R&D
adjust
$-207.88M
Other Operating Expense
adjust
$-10.68M
Operating Income
subtotal
$-256.03M
Other / Non-Operating Items
adjust
$-95.37M
Net Income
subtotal
$-351.40M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about IBRX.US!